STAT+: Pharmalittle: Most doctors disagree with FDA approval of the Alzheimer’s drug; women underrepresented in life sciences C-suites

Good morning, everyone, and how are you today? The heat continues to rise here on the Pharmalot campus, where we are hoping for storm clouds to wash away the humidity that has characterized the past few days. One can dream, yes? To cope, we are quaffing some cups of stimulation and distracting ourselves by foraging for items of interest. Toward that end, we have assembled a few below. Hope you find these helpful and have a cool day. Keep in touch. …

A majority of U.S. physicians disagree with the Food and Drug Administration’s approval of the Alzheimer’s drug from Biogen (BIIB) and believe the medicine should not be routinely used, according to a new survey from STAT and Medscape. Nearly two-thirds of the 200 primary care physicians and neurologists polled find the trial data unclear when it comes to benefits and risks of the drug. Consequently, only a small minority of these doctors think the medicine should be given to patients with early-onset Alzheimer’s.

Continue to STAT+ to read the full story…